La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Botanix Pharmaceuticals Dividendo

Dividendo criteri di controllo 0/6

Botanix Pharmaceuticals non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	2.1%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-AU$0.0055
Previsione del rendimento del dividendo a 3 anni	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Sep 06

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Jan 03

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Sep 05

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

May 10

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Jan 24

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Nov 30

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di BOT siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di BOT siano aumentati.

Rendimento dei dividendi rispetto al mercato

Botanix Pharmaceuticals Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di BOT rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (BOT)	n/a
Fondo del 25% del mercato (AU)	2.5%
Top 25% del mercato (AU)	6.2%
Media del settore (Pharmaceuticals)	2.1%
Previsione dell'analista in 3 anni (BOT)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di BOT rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di BOT rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di BOT per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché BOT non ha segnalato alcun pagamento.

Botanix Pharmaceuticals Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.

New major risk - Financial position

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

New minor risk - Financial position

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

New minor risk - Share price stability

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review

Less than half of directors are independent

Botanix Pharmaceuticals Limited Promotes Howie Mckibbon to Chief Operating Officer

Botanix Pharmaceuticals Limited Announces Positive Data from its BTX 1702 Phase 1B/2 Papulopustular Rosacea Clinical Study

Botanix Pharmaceuticals Limited Submits FDA New Drug Application for Sofpironium Bromide

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 03, 2022

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)

MD, President & Executive Chairman exercised options to buy AU$370k worth of stock.

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Less than half of directors are independent

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Commercial Officer and Patricia Walker as Chief Medical Adviser

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)

We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

Botanix Pharmaceuticals Limited Announces Results from BTX 1204A Pilot Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)

Botanix Pharmaceuticals Limited Expands Management Team

Botanix Pharmaceuticals Limited Announces Positive Top-Line Data from BTX 1801 Phase 2A Nasal Decolonisation Proof of Concept Study

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Botanix Pharmaceuticals Limited Publishes Antimicrobial Data in Peer-Reviewed Research Journal

Botanix Pharmaceuticals Limited Provides Update on BTX 1801 Phase 2A Clinical Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Botanix Pharmaceuticals Limited(ASX:BOT) dropped from S&P/ASX Emerging Companies Index

Full year earnings released - AU$0.018 loss per share

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti